Ophthalmic Drugs Market - Global Industry Analysis

Ophthalmic Drugs Market

Ophthalmic Drugs Market By Disease (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, and Others), By Drug Class (Antiallergy, Anti-VEGF Agents, Anti-inflammatory, Antiglaucoma, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), By Route Of Administration (Topical, Local Ocular, and Systemic), By Product Type (Prescription Drugs and OTC Drugs), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 09-May-2022 Category: Pharmaceutical Report Format : PDF Pages: 180 Report Code: ZMR-3372 Status : Published

The global ophthalmic drugs market was valued at USD 38.13 billion in 2021 and is predicted to expand to USD 60.31 billion by 2028, with a CAGR of roughly 5.9%. The report looks at the ophthalmic drugs market's drivers, limitations, and difficulties, as well as their influence on demand during the projection period.

Description

Ophthalmic Drugs Market: Industry Prospective

The global ophthalmic drugs market was valued at USD 38.13 billion in 2021 and is predicted to expand to USD 60.31 billion by 2028, with a CAGR of roughly 5.9%. The report looks at the ophthalmic drugs market's drivers, limitations, and difficulties, as well as their influence on demand during the projection period. The report will also discuss new opportunities in the field of ophthalmic drugs.

Ophthalmic Drugs Market: Overview

There are many different types of eye disorders and diseases. Preventable blindness and visual impairment are caused by refractive errors, glaucoma, and cataracts. Some of the most prevalent causes of eye disorders are smoking, genetics, chemical irritants, vitamin inadequacy, allergies, and infection. Ophthalmic drugs are a diverse group of medications, each of which serves a distinct role in ophthalmic therapy or operation.

COVID-19 Impact:

The COVID-19 pandemic had an impact on the global ophthalmic drugs market, which is mostly due to the lockdown imposed by key countries. Only emergency operations were being conducted at hospitals or eye clinics, and the number of visits to the eye clinics has also decreased during the pandemic. Since many ophthalmic medications are prescription drugs that cannot be purchased without a doctor's visit, the market is anticipated to suffer as a result of the outbreak. On the other hand, the market is expected to develop as the number of instances of COVID-19 and COVID-19-related eye problems rises. According to new research in the Indian Journal of Ophthalmology, 31.6 percent of COVID-19 patients in China had ocular involvement, with 91.7 percent of COVID-19 patients testing positive for associated eye infections.

Global Ophthalmic Drugs Market

Ophthalmic Drugs Market: Growth Drivers

Growing prevalence of eye-related disorders is fueling the market growth

The global need for ophthalmic drugs is growing as the frequency of eye diseases rises. Eye diseases have already surfaced as possible dangers to people's visual experience in many developed and developing countries. Diabetes treatment has been introduced as the prevalence of diabetes has increased in many nations as it leads to diabetic retinopathy. Because of the difficulties in detecting glaucoma early and the requirement for long-term treatment, glaucoma has been on the healthcare agenda for millennia. In 2021, according to the WHO, over 2.2 billion individuals have blindness or visual impairment, with at least 1 billion of those having a vision impairment that can be avoided. The 1 billion population consists of those with severe or limited vision impairment due to trachoma, diabetic retinopathy, corneal opacities, glaucoma, cataract, and unresolved refractive error, as well as those with imminent vision impairment due to unspecified presbyopia. The growing geriatric population is exacerbating the prevalence of ocular disorders, with uncorrected refractive errors and cataracts being the leading causes of visual impairment. The majority of persons with visual problems are above the age of 50. All such factors are fostering the market growth.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Ophthalmic Drugs Market: Restraints

Side effects associated with the ophthalmic drugs to restrain the market growth

Ophthalmic medications have their own set of side effects. Some of the common side effects that have a tendency to have a severe expression include eye itching, red eyes, eye inflammation, and skin rash. Further, some drugs may also have infrequent side effects for the user which include eye irritation and blurred vision. Some of the patients also experience some rare side effects with the use of the ophthalmic drug that consists of increased intraocular pressure, inflammation of the cornea (keratitis), sensitivity to light & redness of the eye, conjunctival hemorrhage, and many more. All such side effects related to ophthalmic drugs may limit the growth of the market.

Ophthalmic Drugs Market: Opportunities

Increasing approvals of the therapeutics to boost the market growth during the forecast period.

The number of innovative treatments approved by the FDA is increasing. As a result, there is a huge requirement for advanced ophthalmology drugs. The most recent ophthalmic medication trend is to achieve enough drug concentrations at the targeted area of the eye while eliminating adverse effects. The global ophthalmic drugs market is expected to benefit from the growing investment by the market players for pipeline expansion, as well as increased approvals for the introduction of therapeutic drugs thereby driving the growth of the market during the forecast period.

Ophthalmic Drugs Market: Challenges

Issues related to ocular drug delivery to act as a challenge for market growth

One of the most attractive and difficult issues faced by pharmaceutical researchers is ocular drug delivery. Obtaining and maintaining a therapeutic dose at the site of action for an extended period of time is one of the fundamental challenges of ocular medication. The barriers that protect the eye make ocular medication distribution difficult. The active pharmacological substance's bioavailability is sometimes the most difficult barrier to overcome. Traditional ocular dose forms, such as eye drops, are no longer effective in the fight against ocular diseases. In addition to this, to maintain an effective medication level, the drug product must be administered on a regular basis. This, however, can result in toxicity & overdose which are two issues that need to be addressed, patient compliance suffers as a result of the added inconvenience, dealing with a high-priced active pharmaceutical ingredient, may lead to the high cost of the drug. All these factors may act as major challenges for market growth.

Ophthalmic Drugs Market: Segmentation

The global ophthalmic drug market is categorized based on disease, drug class, dosage form, route of administration, product type, and region. By disease, the market is classified into retinal disorders, eye infection, glaucoma, eye allergy, dry eye, and others. Based on the drug class, the market is bifurcated into antiglaucoma, anti-inflammatory, anti-VEGF agents, antiallergy, and others. The dosage form segment comprises ointments, eye drops, capsules & tablets, eye solutions, and gels. The route of administration segment is split into systemic, local ocular, and topical. By product type, the market is classified into OTC drugs and prescription drugs.

Recent Developments

  • In March 2021, Alcon revealed an agreement with Novartis to acquire exclusive marketing rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic solution) 1 percent /0.2 percent in the United States.
  • In March 2022, Novartis received approval for Beovu® from the European Commission for adults with Diabetic macular edema. Year one results from the Phase III KESTREL and KITE studies, which compared Beovu (brolucizumab) 6 mg to aflibercept 2 mg in Diabetic macular edema patients, were used to get approval.

Ophthalmic Drugs Market: Regional Landscape

North America to rule the market during the forecast period.

North America is predicted to dominate the global ophthalmic drugs market during the forecast period, accounting for major revenue, owing to the high consumer awareness and availability of superior healthcare infrastructure and availability of superior healthcare infrastructure. Furthermore, the presence of prominent competitors in this region, such as Alcon and Pfizer, Inc., is projected to boost the market growth. Over the projection period, Asia Pacific is expected to be the fastest-growing region in the market. In Asia Pacific, the rising consumer awareness and increased prevalence of ocular diseases are projected to fuel market expansion. Local businesses are launching strategic endeavors to develop and market innovative patient care solutions. As a result, market growth is likely to accelerate.

Ophthalmic Drugs Market: Competitive Landscape

Some of the key players operating in the global ophthalmic drugs market include NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD, BAUSCH & LOMB INCORPORATED, Alcon, Inc., ABBVIE Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD., SUN PHARMACEUTICAL INDUSTRIES LIMITED, SANTEN PHARMACEUTICAL CO., LTD, REGENERON PHARMACEUTICALS INC., and PFIZER INC.

The global ophthalmic drugs market is segmented as follows:

By Disease

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Eye Infection
  • Retinal Disorders
  • Others

By Drug Class

  • Antiallergy
  • Anti-VEGF Agents
  • Anti-inflammatory
  • Antiglaucoma
  • Others

By Dosage Form

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

By Route of Administration

  • Topical
  • Local Ocular
  • Systemic

By Product Type

  • Prescription Drugs
  • OTC Drugs

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

Ophthalmology deals with the diagnosis, treatment, and prevention of diseases which are associated with the visual system. Most of the eye-related disorders occur over a long period of time and at initial phase are usually asymptomatic or cause a slight decrease in the vision. However, over time this becomes quite distinct. Ophthalmologic disorders cannot be cured completely; however, the treatment aims at managing the disease indication to reduce the severity or slow its progression. Ophthalmologists provide around 85% of their procedure-based services to the seniors. Cataract surgery is the most frequent surgical procedure which is performed in many countries. 

Factors driving the ophthalmic drugs market are the increasing focus of the market players in the emerging economies to tap the unmet medical needs, increasing number of co-development agreements among leading players to make novel biological drugs which have less treatment duration, high proportion of visually challenged population, and generic manufacturers trying to strengthen their distribution networks for cost-effective drugs in developing regions. Moreover, rising prevalence of intraocular eye disorders, age-related macular degeneration, glaucoma, diabetic retinopathy, etc., in the elderly population is also boosting the global ophthalmic drugs market growth. Several organizations globally are increasing allocations on investments in research and development to come up with more effective novel biological agents. However, some of the factors like longer approval timelines required for ophthalmic drugs and loss of patent protection for drugs can hinder the market growth for ophthalmic drugs.

Global Ophthalmic Drugs Market

The ophthalmic drugs market is segmented based on drug type, disease indication, type, and distribution channel. Based on drug class, the market is segmented into anti-inflammatory drugs, antiglaucoma drugs, anti-allergic drugs, anti-infective drugs, and others. The anti-inflammatory drugs are further segmented into nonsteroidal anti-inflammatory drugs and steroids. The anti-infective drugs are further divided into anti-fungal drugs, anti-viral drugs, antibacterial drugs, and others. The anti-glaucoma drugs are segmented into combined medication, alpha agonist, prostaglandin analogs, beta blockers, and others. Based on type, the market is segmented into hospital prescription drugs and over-the-counter drugs. The ophthalmic drugs market is divided on the basis of disease indication into dry eye, allergies, glaucoma, retinal disorders, inflammation/infection, uveitis, and others. Based on the distribution channel, the market is segmented into online sales, retail pharmacies, hospital pharmacies, and others.

North America holds the largest share in the ophthalmic drugs market. This growth is mainly attributed to the huge number of R&D activities in the field of drug discovery. The region also has a large presence of a number of multinational biotech and pharma companies which carry out a large number of clinical trials and also have well developed and advanced healthcare infrastructure. Due to the high healthcare investment and rising government funding, Europe also holds a maximum share of the market followed by North America. Numerous market players are actively involved in the expansion of existing ophthalmic drugs to meet the rising demands for treatment of eye diseases. Besides, approval of new drugs for treating eye disorders by the European Union is also propelling the market for ophthalmic drugs in Europe. Asia Pacific region is also witnessing significant growth rate owing to the unmet health care needs and government funding towards research activities. Numerous ophthalmology companies are investing in the relatively untapped markets in the region to grow their revenue. India, China, and Malaysia are the most attractive markets in Asia Pacific owing to its rising healthcare spendings, substantial consumer base, and patient inclination to avail improved healthcare facilities.

Some of the leading players in ophthalmic drugs market include Allergan Plc, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Novartis AG, Bayer AG, F.Hoffmann-La Roche Ltd., Santen Pharmaceutical Co. Ltd., Kyowa Hakka Kirin Co. Ltd., Valent Pharmaceuticals International, Inc., Johnson and Johnson Vision Care, Inc., and Shire Plc. In March 2017, Allergan selected Aptar Pharma’s ophthalmic squeeze dispenser system for its new dry eye product, Restasis Multidose to treat the patients with the chronic dry eye. 

FrequentlyAsked Questions

Growing prevalence of eye-related disorders is fueling the market growth. Further, the growing geriatric population is exacerbating the prevalence of ocular disorders, with uncorrected refractive errors and cataracts being the leading causes of visual impairment. The majority of persons with visual problems are above the age of 50. All such factors are fostering market growth.

According to the Zion Market Research report, the global ophthalmic drugs market was worth about 38.13 (USD billion) in 2021 and is predicted to grow to around 60.31 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 5.9 percent.

North America is predicted to dominate the global ophthalmic drugs market during the forecast period, accounting for major revenue, owing to the high consumer awareness and availability of superior healthcare infrastructure and availability of superior healthcare infrastructure. Furthermore, the presence of prominent competitors in this region, such as Alcon and Pfizer, Inc., is projected to boost the market growth.

Some of the key players operating in the global ophthalmic drugs market include NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD, BAUSCH & LOMB INCORPORATED, Alcon, Inc., ABBVIE Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD., SUN PHARMACEUTICAL INDUSTRIES LIMITED, SANTEN PHARMACEUTICAL CO., LTD, REGENERON PHARMACEUTICALS INC., and PFIZER INC.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed